J Korean Med Sci.  2016 Nov;31(11):1808-1813. 10.3346/jkms.2016.31.11.1808.

Risk Factor Analysis of Ciprofloxacin-Resistant and Extended Spectrum Beta-Lactamases Pathogen-Induced Acute Bacterial Prostatitis in Korea

• Lee Y
• Lee DG
• Lee SH
• Yoo KH

• KMID: 2470279
• DOI: http://doi.org/10.3346/jkms.2016.31.11.1808

Abstract

The objectives of this study were to investigate risk factors and the incidence of ciprofloxacin resistance and extended-spectrum beta-lactamases (ESBL) in patients with acute bacterial prostatitis (ABP). We reviewed the medical records of 307 patients who were diagnosed with ABP between January 2006 and December 2015. The etiologic pathogens and risk factors for ciprofloxacin-resistant E. coli and ESBL-producing microbes, susceptibility to ciprofloxacin, and the incidence of ESBL in patients with ABP were described. History of prior urologic manipulation was an independent risk factor for ciprofloxacin-resistant (P = 0.005) and ESBL-producing microbes (P = 0.005). Advanced age (over 60 years) was an independent risk factor for ciprofloxacin-resistant microbes (P = 0.022). The ciprofloxacin susceptibility for Escherichia coli in groups without prior manipulation was documented 85.7%. For groups with prior manipulation, the susceptibility was 10.0%. Incidence of ESBL-producing microbes by pathogen was 3.8% for E. coli and 1.0% for Klebsiella pneumonia in the absence of manipulation group, and 20% and 33.3% in the presence of manipulation group, respectively. Initial treatment of ABP must consider patient's age and the possibility of prior manipulation to optimize patient treatment. With the high rate of resistance to fluoroquinolone, cephalosporins with amikacin, or carbapenems, or extended-spectrum penicillin with beta lactamase inhibitor should be considered as the preferred empirical ABP treatment in the patients with history of prior urologic manipulation.

Keyword

Acute Bacterial Prostatitis; Ciprofloxacin; Extended-spectrum Beta-lactamases; Risk Factors

MeSH Terms

Acute Disease
Adult
Age Factors
Aged
Amikacin/pharmacology
Anti-Bacterial Agents/pharmacology/*therapeutic use
Bacterial Infections/diagnosis/*drug therapy/microbiology
Cephalosporins/pharmacology
Ciprofloxacin/*therapeutic use
*Drug Resistance, Bacterial
Escherichia coli/drug effects/enzymology/isolation & purification
Humans
Imipenem/pharmacology
Klebsiella pneumoniae/drug effects/enzymology/isolation & purification
Male
Microbial Sensitivity Tests
Middle Aged
Multivariate Analysis
Odds Ratio
Prostatitis/*diagnosis/drug therapy/microbiology
Republic of Korea
Retrospective Studies
Risk Factors
beta-Lactamases/*metabolism
Anti-Bacterial Agents
Cephalosporins
Ciprofloxacin
Imipenem
Amikacin

Reference

1. Krieger JN, Lee SW, Jeon J, Cheah PY, Liong ML, Riley DE. Epidemiology of prostatitis. Int J Antimicrob Agents. 2008; 31:Suppl 1. S85–90.

2. Neal DE Jr. Acute bacterial prostatitis. In: Nickel JC, editor Textbook of Prostatitis. Oxford: Isis Medical Media;1999. p. 115–121.

3. Sharp VJ, Takacs EB, Powell CR. Prostatitis: diagnosis and treatment. Am Fam Physician. 2010; 82:397–406.

4. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection. Arch Intern Med. 2005; 165:1375–1380.

5. Naber KG, Sörgel F. Antibiotic therapy--rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia. 2003; 35:331–335.

6. Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother. 2012; 56:2181–2183.

7. Jun KI, Koo HL, Kim MK, Kang CK, Kim MJ, Chun SH, Song JS, Kim HS, Kim NJ, Kim EC, et al. Trends in antibiotic use in a single university hospital. Korean J Nosocomial Infect Control. 2013; 18:44–50.

8. Shin J, Kim J, Wie SH, Cho YK, Lim SK, Shin SY, Yeom JS, Lee JS, Kweon KT, Lee H, et al. Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact. Microb Drug Resist. 2012; 18:169–175.

9. Hsueh PR, Hoban DJ, Carmeli Y, Chen SY, Desikan S, Alejandria M, Ko WC, Binh TQ. Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. J Infect. 2011; 63:114–123.

10. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005; 18:657–686.

11. Li XM, Jang SJ, Bae IK, Park G, Kim YS, Shin JH, Moon DS, Park YJ. Frequency of extended-spectrum beta-lactamase (ESBL) and AmpC beta-lactamase genes in Escherichia coli and Klebsiella pneumoniae over a three-year period in a University Hospital in Korea. Korean J Lab Med. 2010; 30:616–623.

12. Blaettler L, Mertz D, Frei R, Elzi L, Widmer AF, Battegay M, Flückiger U. Secular trend and risk factors for antimicrobial resistance in Escherichia coli isolates in Switzerland 1997-2007. Infection. 2009; 37:534–539.

13. Nicoletti J, Kuster SP, Sulser T, Zbinden R, Ruef C, Ledergerber B, Weber R. Risk factors for urinary tract infections due to ciprofloxacin-resistant Escherichia coli in a tertiary care urology department in Switzerland. Swiss Med Wkly. 2010; 140:w13059.

14. Lee G, Cho YH, Shim BS, Lee SD. Risk factors for antimicrobial resistance among the Escherichia coli strains isolated from Korean patients with acute uncomplicated cystitis: a prospective and nationwide study. J Korean Med Sci. 2010; 25:1205–1209.

15. Eshwarappa M, Dosegowda R, Aprameya IV, Khan MW, Kumar PS, Kempegowda P. Clinico-microbiological profile of urinary tract infection in south India. Indian J Nephrol. 2011; 21:30–36.

16. Stamey TA, Fair WR, Timothy MM, Millar MA, Mihara G, Lowery YC. Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N Engl J Med. 1974; 291:1159–1163.

17. Ekici S, Cengiz M, Turan G, Alış EE. Fluoroquinolone-resistant acute prostatitis requiring hospitalization after transrectal prostate biopsy: effect of previous fluoroquinolone use as prophylaxis or long-term treatment. Int Urol Nephrol. 2012; 44:19–27.

18. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999; 282:236–237.

19. Yoon BI, Kim S, Han DS, Ha US, Lee SJ, Kim HW, Han CH, Cho YH. Acute bacterial prostatitis: how to prevent and manage chronic infection? J Infect Chemother. 2012; 18:444–450.

20. Ha US, Kim ME, Kim CS, Shim BS, Han CH, Lee SD, Cho YH. Acute bacterial prostatitis in Korea: clinical outcome, including symptoms, management, microbiology and course of disease. Int J Antimicrob Agents. 2008; 31:Suppl 1. S96–101.

21. Kim SH, Ha US, Yoon BI, Kim SW, Sohn DW, Kim HW, Cho SY, Cho YH. Microbiological and clinical characteristics in acute bacterial prostatitis according to lower urinary tract manipulation procedure. J Infect Chemother. 2014; 20:38–42.

22. Yoon BI, Han DS, Ha US, Lee SJ, Sohn DW, Kim HW, Han CH, Cho YH. Clinical courses following acute bacterial prostatitis. Prostate Int. 2013; 1:89–93.

23. Blanco M, Blanco JE, Alonso MP, Blanco J. Virulence factors and O groups of Escherichia coli isolates from patients with acute pyelonephritis, cystitis and asymptomatic bacteriuria. Eur J Epidemiol. 1996; 12:191–198.

24. Svanborg C, Godaly G. Bacterial virulence in urinary tract infection. Infect Dis Clin North Am. 1997; 11:513–529.

25. Martínez-Martínez L, Fernández F, Perea EJ. Relationship between haemolysis production and resistance to fluoroquinolones among clinical isolates of Escherichia coli . J Antimicrob Chemother. 1999; 43:277–279.

26. Velasco M, Horcajada JP, Mensa J, Moreno-Martinez A, Vila J, Martinez JA, Ruiz J, Barranco M, Roig G, Soriano E. Decreased invasive capacity of quinolone-resistant Escherichia coli in patients with urinary tract infections. Clin Infect Dis. 2001; 33:1682–1686.

27. Rowe TA, Juthani-Mehta M. Urinary tract infection in older adults. Aging Health. 2013; 9:519–528.

28. Siriboon S, Tiengrim S, Taweemongkongsup T, Thamlikitkul V, Chayakulkeeree M. Prevalence of antibiotic resistance in fecal flora of patients undergoing transrectal ultrasound-guided prostate biopsy in Thailand. Urol Int. 2012; 88:187–193.

29. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli . J Infect. 2007; 55:254–259.

30. Naber KG, Bergman B, Bishop MC, Bjerklund-Johansen TE, Botto H, Lobel B, Jinenez Cruz F, Selvaggi FP; Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur Urol. 2001; 40:576–588.